Immune Checkpoint Inhibitors Market Size, Trends, Share, Growth Analysis Report, COVID-19 Impact & Forecast

 

  Immune checkpoint inhibitors are a type of immunotherapy drug. Although traditional chemotherapeutic drugs are still the first-line treatment option for most cancer types, targeted immune therapies are becoming standard treatments for advanced-stage cancers. These drugs target cell surface checkpoint proteins to stimulate the immune system's recognition and destruction of cancer cells.

  The global immune checkpoint inhibitors market is growing due to an increase in cancer prevalence across geographies and increased awareness of immune checkpoint inhibitors. Furthermore, technological advancements in cancer screening procedures, increased healthcare expenditures, an increase in government initiatives to alleviate cancer, and an increase in public awareness is expected to drive market growth.

 The human body's immune system is dependent on multiple checkpoints or immunological breaks that prevent the over-activation of healthy cells or the immune system. Tumor or cancerous cells frequently use these checkpoints to avoid detection and fight the immune system. To combat such cancer cells, scientists and drug developers are increasingly turning to immunotherapeutics, which use the body's own immune system or its components to fight cancer. Although targeted-based therapeutics such as conjugated and monoclonal antibodies have yielded promising results, there has been a surge of interest in other classes of immunotherapeutics to treat and manage cancer, such as immune checkpoint inhibitors, whole cell-based therapies, and therapeutic cancer vaccines.

  Because of the global increase in lung cancer prevalence, the lung cancer segment currently dominates the market and is expected to remain dominant during the forecast period. The increased use of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC) also contributes to the growth of this segment. Furthermore, an increase in the geriatric population, an increase in the cigarette smoking population, and advancements in lung cancer diagnostic techniques all contribute to market growth.

  However, the high cost associated with product research and development raises the cost of the final product and associated treatment, which is expected to stymie the growth of the immune checkpoint inhibitors market. Furthermore, the high cost of immune checkpoint inhibitors has resulted in regulatory price caps. The regulatory price caps on immune checkpoint inhibitors are also expected to stymie the market's growth.

  Bristol-Myers Squibb Company, Astra Zeneca plc, Merck & Co., Pfizer, Inc., F. Hoffmann-La Roche AG, Incyte Corporation, NewLink Genetics Corporation, Seattle Genetics, Inc., Celldex Therapeutics, GlaxoSmithKline plc, and Innate Pharma S.A. are among the major players involved in immune checkpoint inhibitor research and development.